Jounce Therapeutics IPO

1/26/2017

IPO

$102,000,000

We are undertaking this offering in order to access the public capital markets and to increase our liquidity. We anticipate that we will use the net proceeds received by us in this offering, together with our existing cash, cash equivalents, and marketable securities, as follows: approximately $30.0 million to advance JTX-2011 through the completion of our multi-arm Phase I/II clinical trial, designed to provide safety and dosing data, and clinical proof of concept efficacy data for JTX-2011 both as a single agent and in combination with other therapies; approximately $25.0 million to advance JTX-4014 through Investigational New Drug, or IND, enabling studies and filings, and planned initial clinical studies for development as a combination agent; approximately $10.0 million to continue to advance and expand our Translational Science Platform, and research and development pipeline, including both internal and external costs for IND enabling studies and early discovery efforts, includin

Publicly-held

Biopharmaceutical

780 Memorial Dr.
Cambridge, MA 02138
USA

Not Recorded

Jounce Therapeutics (NASDAQ: JNCE) is focused on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.